ÀÇ·áÁø ã±â
¾Æ·¡ °Ë»öÀ» ÅëÇØ Á¤È®ÇÏ°í ºü¸£°Ô ÀÇ·áÁøÀ» °Ë»öÇÒ ¼ö ÀÖ½À´Ï´Ù.
Áø·á°ú ¾È³»
[¹®ÀÇÀüÈ] 1577-9966
Áø·á°ú¸¦ ¾È³»ÇØ µå¸³´Ï´Ù. Ŭ¸¯ ½Ã ÇØ´ç Áø·á°úÀÇ ÀÚ¼¼ÇÑ »çÇ×À» º¸½Ç ¼ö ÀÖ½À´Ï´Ù.
Á¾¾ç³»°ú
-
[SCI]
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
/ Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
/ 2020;52:254-62.
/ 202005
-
[SCI]
The clinical outcomes of rituximab biosimilar CT-P10 (Truxima((R))) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience.
/ The clinical outcomes of rituximab biosimilar CT-P10 (Truxima((R))) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience.
/ 2020:1-9.
/ 202005
-
[SCI]
The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions
/ The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions
/ 202005
-
[SCI]
Impact of subsequent chemotherapy on the survival of elderly patients with extensive stage small cell lung cancer.
Kang EJ, Choi YJ, Lee SR, Sung HJ, Kim JS.
/ Impact of subsequent chemotherapy on the survival of elderly patients with extensive stage small cell lung cancer.
/ 2020 Apr 29. doi: 10.3904/kjim.2019.136
/ 202004
-
[SCI]
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
.Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
/ Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
/ 2019 Dec 11:JCO1900931
/ 201912